| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Simulations Plus Inc (NASDAQ: SLP)
SLP Technical Analysis
1.5
| As on 9th Jun 2023 SLP SHARE Price closed @ 44.95 and we RECOMMEND Sell for LONG-TERM with Stoploss of 48.75 & Buy for SHORT-TERM with Stoploss of 43.56 we also expect STOCK to react on Following IMPORTANT LEVELS. |
SLPSHARE Price
| Open | 46.75 | Change | Price | % |
| High | 47.76 | 1 Day | -1.87 | -3.99 |
| Low | 44.69 | 1 Week | -0.08 | -0.18 |
| Close | 44.95 | 1 Month | 2.05 | 4.78 |
| Volume | 98700 | 1 Year | -2.88 | -6.02 |
| 52 Week High 66.88 | 52 Week Low 34.96 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| SLP Daily Charts |
SLP Intraday Charts |
Whats New @ Bazaartrend |
SLP Free Analysis |
|
|
SLP Important Levels Intraday
| RESISTANCE | 50.87 |
| RESISTANCE | 48.97 |
| RESISTANCE | 47.80 |
| RESISTANCE | 46.62 |
| SUPPORT | 43.28 |
| SUPPORT | 42.10 |
| SUPPORT | 40.93 |
| SUPPORT | 39.03 |
SLP Forecast April 2024
| 4th UP Forecast | 72.18 |
| 3rd UP Forecast | 63.45 |
| 2nd UP Forecast | 58.05 |
| 1st UP Forecast | 52.65 |
| 1st DOWN Forecast | 37.25 |
| 2nd DOWN Forecast | 31.85 |
| 3rd DOWN Forecast | 26.45 |
| 4th DOWN Forecast | 17.72 |
SLP Weekly Forecast
| 4th UP Forecast | 55.61 |
| 3rd UP Forecast | 52.19 |
| 2nd UP Forecast | 50.08 |
| 1st UP Forecast | 47.96 |
| 1st DOWN Forecast | 41.94 |
| 2nd DOWN Forecast | 39.82 |
| 3rd DOWN Forecast | 37.71 |
| 4th DOWN Forecast | 34.29 |
SLP Forecast2024
| 4th UP Forecast | 112.32 |
| 3rd UP Forecast | 90.71 |
| 2nd UP Forecast | 77.36 |
| 1st UP Forecast | 64 |
| 1st DOWN Forecast | 25.9 |
| 2nd DOWN Forecast | 12.54 |
| 3rd DOWN Forecast | -0.81 |
| 4th DOWN Forecast | -22.42 |
Simulations Plus Inc ( NASDAQ USA Symbol : SLP )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
SLP Business Profile
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California. Address: 42505 Tenth Street West, Lancaster, CA, United States, 93534-7059
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service